Moyamoya disease: diagnosis and interventions

[1]  M. Vikkula,et al.  Recalibrating vascular malformations and mechanotransduction by pharmacological intervention , 2022, The Journal of clinical investigation.

[2]  S. Kuroda,et al.  2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society , 2022, Neurologia medico-chirurgica.

[3]  B. Neel,et al.  MMD-associated RNF213 SNPs encode dominant-negative alleles that globally impair ubiquitylation , 2022, Life Science Alliance.

[4]  R. Tamargo,et al.  Revascularization of Hemorrhagic Moyamoya Disease in a North American Cohort: The Role of Timing in Perioperative and Long-Term Outcomes , 2022, Neurosurgery.

[5]  C. Ogilvy,et al.  Asymptomatic moyamoya disease in a North American adult cohort. , 2022, World neurosurgery.

[6]  Jing Zhao,et al.  A meta‐analysis of comparisons of various surgical treatments for moyamoya diseases , 2021, Brain and behavior.

[7]  K. Ogasawara,et al.  Five-Year Outcomes of Medical Management Alone for Adult Patients with Ischemic Moyamoya Disease without Cerebral Misery Perfusion , 2021, Cerebrovascular Diseases.

[8]  O. Akel,et al.  Experimental animal models for moyamoya disease and treatment: a pathogenesis-oriented scoping review. , 2021, Neurosurgical focus.

[9]  Akinobu Ota,et al.  Transcriptome-wide analysis of intracranial artery in patients with moyamoya disease showing upregulation of immune response, and downregulation of oxidative phosphorylation and DNA repair. , 2021, Neurosurgical Focus.

[10]  Min S. Park,et al.  Experimental animal models for the study of moyamoya disease. , 2021, Neurosurgical focus.

[11]  Qian Zhang,et al.  The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. , 2021, Neurosurgical focus.

[12]  T. Kawaguchi,et al.  The association between the Moyamoya disease susceptible gene RNF213 variant and incident cardiovascular disease in a general population: the Nagahama study , 2021, Journal of hypertension.

[13]  N. Saito,et al.  Differences in Clinical Features among Different Onset Patterns in Moyamoya Disease , 2021, Journal of clinical medicine.

[14]  Amber N. Stratman,et al.  DIAPH1 Variants in Non-East Asian Patients With Sporadic Moyamoya Disease. , 2021, JAMA neurology.

[15]  K. Knobeloch,et al.  Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity , 2021, Nature Communications.

[16]  Elsje G. Otten,et al.  Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection , 2021, Nature.

[17]  T. Tominaga,et al.  Dysregulation of Rnf 213 gene contributes to T cell response via antigen uptake, processing, and presentation , 2021, Journal of cellular physiology.

[18]  T. Clausen,et al.  E3 ubiquitin ligase RNF213 employs a non-canonical zinc finger active site and is allosterically regulated by ATP , 2021, bioRxiv.

[19]  H. Hakonarson,et al.  A new syndrome of moyamoya disease, kidney dysplasia, aminotransferase elevation, and skin disease associated with de novo variants in RNF213 , 2021, American journal of medical genetics. Part A.

[20]  Aman B Patel,et al.  Direct vs Indirect Revascularization in a North American Cohort of Moyamoya Disease , 2021, Neurosurgery.

[21]  J. Saver,et al.  Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study , 2021, Journal of the American Heart Association.

[22]  Seung-Chyul Hong,et al.  Prospective Screening of Extracranial Systemic Arteriopathy in Young Adults with Moyamoya Disease , 2020, Journal of the American Heart Association.

[23]  Rong Wang,et al.  Characteristics of cognitive impairment in adult asymptomatic moyamoya disease , 2020, BMC Neurology.

[24]  M. L. Dell'Acqua,et al.  Vascular Remodeling in Moyamoya Angiopathy: From Peripheral Blood Mononuclear Cells to Endothelial Cells , 2020, International journal of molecular sciences.

[25]  S. Tsuji,et al.  Comprehensive investigation of RNF213 nonsynonymous variants associated with intracranial artery stenosis , 2020, Scientific Reports.

[26]  D. Haselbach,et al.  Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. , 2020, eLife.

[27]  B. Bender,et al.  Arterial wall contrast enhancement in progressive moyamoya disease. , 2020, Journal of Neurosurgery.

[28]  N. Saito,et al.  Association Between the Onset Pattern of Adult Moyamoya Disease and Risk Factors for Stroke , 2020, Stroke.

[29]  Seung-Chyul Hong,et al.  Moyamoya Disease and Spectrums of RNF213 Vasculopathy , 2019, Translational Stroke Research.

[30]  Yoon-Chul Kim,et al.  Ring Finger Protein 213 Variant and Plaque Characteristics, Vascular Remodeling, and Hemodynamics in Patients With Intracranial Atherosclerotic Stroke: A High‐Resolution Magnetic Resonance Imaging and Hemodynamic Study , 2019, Journal of the American Heart Association.

[31]  K. Houkin,et al.  Characteristics of Moyamoya Disease Based on National Registry Data in Japan. , 2019, Stroke.

[32]  M. Gitlin,et al.  Psychiatric Comorbidity in Moyamoya Disease and Preliminary Guidelines For Treatment. , 2019, The American journal of psychiatry.

[33]  H. Tan,et al.  Rare RNF213 variants and the risk of intracranial artery stenosis/occlusion disease in Chinese population: a case-control study , 2019, BMC Medical Genetics.

[34]  Lei Feng,et al.  Epidemiology, diagnosis and treatment of moyamoya disease. , 2019, Experimental and therapeutic medicine.

[35]  S. Kuroda,et al.  Longitudinal anterior-to-posterior shift of collateral channels in patients with moyamoya disease: an implication for its hemorrhagic onset. , 2019, Journal of neurosurgery.

[36]  K. Ogasawara,et al.  Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort , 2019, Neurological research.

[37]  U. Klose,et al.  Hypercapnic BOLD MRI compared to H215O PET/CT for the hemodynamic evaluation of patients with Moyamoya Disease , 2019, NeuroImage: Clinical.

[38]  S. Kuroda,et al.  High rebleeding risk associated with choroidal collateral vessels in hemorrhagic moyamoya disease: analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. , 2019, Journal of neurosurgery.

[39]  Y. Kamatani,et al.  Moyamoya Disease Susceptibility Variant RNF213 p.R4810K Increases the Risk of Ischemic Stroke Attributable to Large-Artery Atherosclerosis. , 2019, Circulation.

[40]  F. Gao,et al.  TPO-Ab plays a role in arterial remodeling in patients with intracranial stenosis. , 2019, Atherosclerosis.

[41]  Wanyang Liu,et al.  RNF213 p.R4810K Polymorphism and the Risk of Moyamoya Disease, Intracranial Major Artery Stenosis/Occlusion, and Quasi-Moyamoya Disease: A Meta-Analysis. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[42]  K. Yamashita,et al.  4D ASL-based MR angiography for visualization of distal arteries and leptomeningeal collateral vessels in moyamoya disease: a comparison of techniques , 2018, European Radiology.

[43]  Takeshi Kimura,et al.  Rare variants in RNF213, a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxia-induced pulmonary hypertension in mice , 2018, Pulmonary circulation.

[44]  H. Iida,et al.  Dysregulation of RNF213 promotes cerebral hypoperfusion , 2018, Scientific Reports.

[45]  W. Dai,et al.  Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review , 2017, Environmental Health and Preventive Medicine.

[46]  K. Houkin,et al.  Novel insights into symptomatology of moyamoya disease in pediatric patients: survey of symptoms suggestive of orthostatic intolerance. , 2017, Journal of neurosurgery. Pediatrics.

[47]  E. Génin,et al.  Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians , 2017, European Journal of Human Genetics.

[48]  S. Miyamoto,et al.  Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease , 2017, PloS one.

[49]  Lanbing Yu,et al.  RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. , 2017, Journal of neurosurgery.

[50]  M. Brozman,et al.  RNF213 Rare Variants in Slovakian and Czech Moyamoya Disease Patients , 2016, PloS one.

[51]  D. Nickerson,et al.  Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension , 2016, Clinical genetics.

[52]  Yufang Wang,et al.  Mutation of rnf213a by TALEN causes abnormal angiogenesis and circulation defects in zebrafish , 2016, Brain Research.

[53]  Seung-Chyul Hong,et al.  A Polymorphism in RNF213 Is a Susceptibility Gene for Intracranial Atherosclerosis , 2016, PloS one.

[54]  Kazumichi Yoshida,et al.  Periventricular anastomosis in moyamoya disease: detecting fragile collateral vessels with MR angiography. , 2016, Journal of neurosurgery.

[55]  Seung-Chyul Hong,et al.  Determinants of Basal Collaterals in Moyamoya Disease: Clinical and Genetic Factors , 2016, European Neurology.

[56]  G. Zaharchuk,et al.  Acute Preoperative Infarcts and Poor Cerebrovascular Reserve Are Independent Risk Factors for Severe Ischemic Complications following Direct Extracranial-Intracranial Bypass for Moyamoya Disease , 2016, American Journal of Neuroradiology.

[57]  P. Ferroli,et al.  Vasculogenic and Angiogenic Pathways in Moyamoya Disease. , 2016, Current medicinal chemistry.

[58]  A. van der Zwan,et al.  Research Progresses in Understanding the Pathophysiology of Moyamoya Disease , 2016, Cerebrovascular Diseases.

[59]  H. Augustin,et al.  Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling. , 2016, Developmental cell.

[60]  S. Kuroda,et al.  Significance of the Hemorrhagic Site for Recurrent Bleeding: Prespecified Analysis in the Japan Adult Moyamoya Trial , 2016, Stroke.

[61]  Jong S. Kim Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis , 2016, Journal of stroke.

[62]  A. Koizumi,et al.  A new horizon of moyamoya disease and associated health risks explored through RNF213 , 2015, Environmental Health and Preventive Medicine.

[63]  N. Mikuni,et al.  Vascular remodeling of the circle of Willis in moyamoya disease , 2015, Neurological research.

[64]  T. Noguchi,et al.  Noninvasive method for mapping CVR in moyamoya disease using ASL-MRI. , 2015, European journal of radiology.

[65]  P. Vajkoczy,et al.  Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians , 2015, European journal of neurology.

[66]  S. Kuroda Asymptomatic Moyamoya Disease: Literature Review and Ongoing AMORE Study , 2015, Neurologia medico-chirurgica.

[67]  S. Miyamoto,et al.  Cognitive Dysfunction Survey of the Japanese Patients with Moyamoya Disease (COSMO-JAPAN Study): Study Protocol , 2015, Neurologia medico-chirurgica.

[68]  D. Hervé,et al.  The Application of Clinical Genetics Dovepress Moyamoya Disease and Syndromes: from Genetics to Clinical Management , 2022 .

[69]  Seung-Chyul Hong,et al.  High-Resolution Magnetic Resonance Wall Imaging Findings of Moyamoya Disease , 2014, Stroke.

[70]  S. Kuroda,et al.  Effects of Extracranial–Intracranial Bypass for Patients With Hemorrhagic Moyamoya Disease: Results of the Japan Adult Moyamoya Trial , 2014, Stroke.

[71]  T. Tominaga,et al.  Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: A susceptibility gene for moyamoya disease , 2014, Brain Research.

[72]  B. Reizis,et al.  The role of dendritic cells in autoimmunity , 2013, Nature Reviews Immunology.

[73]  A. Butte,et al.  Immune response profiling identifies autoantibodies specific to Moyamoya patients , 2013, Orphanet Journal of Rare Diseases.

[74]  S. Takashima,et al.  Ablation of Rnf213 retards progression of diabetes in the Akita mouse. , 2013, Biochemical and biophysical research communications.

[75]  S. Nanayakkara,et al.  P.R4810K, a polymorphism of RNF213, the susceptibility gene for moyamoya disease, is associated with blood pressure , 2013, Environmental Health and Preventive Medicine.

[76]  A. Mukasa,et al.  Identification of a Genetic Variant Common to Moyamoya Disease and Intracranial Major Artery Stenosis/Occlusion , 2012, Stroke.

[77]  M. Guan,et al.  Molecular Analysis of RNF213 Gene for Moyamoya Disease in the Chinese Han Population , 2012, PloS one.

[78]  T. Hirai,et al.  Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis? , 2012, Acta Neurochirurgica.

[79]  A. Koizumi,et al.  Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations. , 2012, Neurologia medico-chirurgica.

[80]  Y. Kuroiwa,et al.  Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease , 2012, Neurology.

[81]  A. Fujiyama,et al.  Identification of RNF213 as a Susceptibility Gene for Moyamoya Disease and Its Possible Role in Vascular Development , 2011, PloS one.

[82]  Hong Yang,et al.  Increased Thyroid Function and Elevated Thyroid Autoantibodies in Pediatric Patients With Moyamoya Disease: A Case-Control Study , 2011, Stroke.

[83]  G. Zhu,et al.  Phenotype Switch of Vascular Smooth Muscle Cells After siRNA Silencing of Filamin , 2011, Cell Biochemistry and Biophysics.

[84]  M. Lee,et al.  Movement disorders associated with moyamoya disease: A report of 4 new cases and a review of literatures , 2010, Movement disorders : official journal of the Movement Disorder Society.

[85]  Seung-Chyul Hong,et al.  Association of Thyroid Autoantibodies With Moyamoya-Type Cerebrovascular Disease: A Prospective Study , 2010, Stroke.

[86]  R. Scott,et al.  Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.

[87]  S. Kuroda,et al.  Moyamoya disease: current concepts and future perspectives , 2008, The Lancet Neurology.

[88]  Hidenao Fukuyama,et al.  Microbleeds in Moyamoya Disease: Susceptibility-Weighted Imaging Versus T2*-Weighted Imaging at 3 Tesla , 2008, Investigative radiology.

[89]  K. Ikeda,et al.  Asymptomatic Moyamoya disease. , 2007, Stroke.

[90]  H. Seol,et al.  Headache in pediatric moyamoya disease: review of 204 consecutive cases. , 2005, Journal of neurosurgery.

[91]  D. Tirschwell,et al.  Moyamoya disease in Washington State and California , 2005, Neurology.

[92]  N. Sakai,et al.  Studies on cytomegalovirus and Epstein-Barr virus infection in Moyamoya disease , 1997, Clinical Neurology and Neurosurgery.

[93]  S. Miyamoto,et al.  Cerebral revascularization using omental transplantation for childhood moyamoya disease. , 1993, Journal of neurosurgery.

[94]  S. Miyamoto,et al.  Study of the posterior circulation in moyamoya disease. Part 2: Visual disturbances and surgical treatment. , 1984, Journal of neurosurgery.

[95]  S. Kuroda,et al.  Revision 2021 of The Guideline for The Diagnosis of Moyamoya Disease by Research Committee on Moyamoya Disease (Spontaneous Occlusion of Circle of Willis) , 2022, Surgery for Cerebral Stroke.

[96]  Tej D. Azad,et al.  Validation and Application for the Berlin Grading System of Moyamoya Disease in Adult Patients. , 2019, Neurosurgery.

[97]  A. Hata,et al.  A genome-wide association study identifies RNF213 as the first Moyamoya disease gene , 2011, Journal of Human Genetics.